



Company Overview

Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, disruptive cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories.

Avalon GloboCare Announces Grand Opening of Newly Renovated Headquarters in New Jersey

Oct 15 2018, 8:00 AM EDT

Avalon GloboCare Teams Up with Weill Cornell Medicine to Co-develop Standardization of cGMP-Grade Exosome Isolation and Application of Tissue-Specific Exosomes

Oct 9 2018, 9:00 AM EDT

Avalon GloboCare Commences Operation of its Core GMP Platform, Epicon Biotech, to Facilitate Clinical Development of Cellular Therapies

Sep 20 2018, 8:00 AM EDT

Stock Overview

Symbol	AVCO
Exchange	OTCQB
Market Cap	198.61m
Last Price	\$2.70
52-Week	\$0.9839 - \$4.60

10/22/2018 12:30 PM EDT

Investor Relations

Crescendo Communications, LLC
T: (212) 671-1020
avco@crescendo-ir.com

Management Team

David Jin

Chief Executive Officer, President and Director

Meng Li

Chief Operating Officer and Secretary

Luisa Ingargiola

Chief Financial Officer

Avalon GloboCare Corp.

4400 Route 9 South
Suite 3100
Freehold, NJ 07728

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.